 |
5 Diseases |  |
1 Trial |
|
1 Trial |  |
22 News |  |
- ||| GZ402668 / Sanofi
Trial completion: A Long-term Follow-up Study Of Multiple Sclerosis Patients Who Participated In Genzyme-sponsored Studies of GZ402668 (clinicaltrials.gov) - Apr 25, 2022
P=N/A, N=64, Completed, Sponsor: Genzyme, a Sanofi Company
Active, not recruiting --> Completed
- || GZ402668 / Sanofi
Enrollment closed: A Long-term Follow-up Study Of Multiple Sclerosis Patients Who Participated In Genzyme-sponsored Studies of GZ402668 (clinicaltrials.gov) - Dec 23, 2019
P=N/A, N=54, Active, not recruiting, Sponsor: Genzyme, a Sanofi Company
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- GZ402668 / Sanofi
Enrollment open: A Single Ascending Dose Study of GZ402668 in Patients With Progressive Multiple Sclerosis (clinicaltrials.gov) - Apr 2, 2018
P1, N=24, Recruiting, Sponsor: Sanofi
Recruiting --> Active, not recruiting Active, not recruiting --> Recruiting
- || GZ402668 / Sanofi
Enrollment status, Trial primary completion date: A Long-term Follow-up Study Of Multiple Sclerosis Patients Who Participated In Genzyme-sponsored Studies of GZ402668 (clinicaltrials.gov) - Oct 6, 2017
P=N/A, N=72, Recruiting, Sponsor: Genzyme, a Sanofi Company
Active, not recruiting --> Recruiting Enrolling by invitation --> Recruiting | Trial primary completion date: Jul 2021 --> Apr 2022
- GZ402668 / Sanofi
Enrollment closed, Trial primary completion date: A Single Ascending Dose Study of GZ402668 in Patients With Progressive Multiple Sclerosis (clinicaltrials.gov) - Sep 14, 2017
P1, N=24, Active, not recruiting, Sponsor: Sanofi
Enrolling by invitation --> Recruiting | Trial primary completion date: Jul 2021 --> Apr 2022 Recruiting --> Active, not recruiting | Trial primary completion date: Aug 2018 --> Mar 2018
- GZ402668 / Sanofi
Trial primary completion date: A Single Ascending Dose Study of GZ402668 in Patients With Progressive Multiple Sclerosis (clinicaltrials.gov) - Aug 24, 2017
P1, N=24, Recruiting, Sponsor: Sanofi
Recruiting --> Active, not recruiting | Trial primary completion date: Aug 2018 --> Mar 2018 Trial primary completion date: Aug 2017 --> Aug 2018
- || GZ402668 / Sanofi
Enrollment change: A Long-term Follow-up Study Of Multiple Sclerosis Patients Who Participated In Genzyme-sponsored Studies of GZ402668 (clinicaltrials.gov) - Jan 23, 2017
P=N/A, N=72, Enrolling by invitation, Sponsor: Genzyme, a Sanofi Company
Trial primary completion date: Aug 2017 --> Aug 2018 N=48 --> 72
- GZ402668 / Sanofi
Enrollment open: A Single Ascending Dose Study of GZ402668 in Patients With Progressive Multiple Sclerosis (clinicaltrials.gov) - Jan 18, 2017
P1, N=24, Recruiting, Sponsor: Sanofi
N=48 --> 72 Not yet recruiting --> Recruiting
- | GZ402668 / Sanofi
New P1 trial: A Single Ascending Dose Study of GZ402668 in Patients With Progressive Multiple Sclerosis (clinicaltrials.gov) - Nov 30, 2016
P1, N=24, Not yet recruiting, Sponsor: Sanofi
- GZ402668 / Sanofi
Trial primary completion date: A Long-term Follow-up Study Of Multiple Sclerosis Patients Who Participated In Genzyme-sponsored Studies of GZ402668 (clinicaltrials.gov) - Jul 19, 2016
P=N/A, N=48, Enrolling by invitation, Sponsor: Genzyme, a Sanofi Company
Not yet recruiting --> Recruiting Trial primary completion date: Feb 2020 --> May 2021
- GZ402668 / Sanofi
Enrollment status: A Long-term Follow-up Study Of Multiple Sclerosis Patients Who Participated In Genzyme-sponsored Studies of GZ402668 (clinicaltrials.gov) - Apr 14, 2016
P=N/A, N=48, Enrolling by invitation, Sponsor: Genzyme, a Sanofi Company
Trial primary completion date: Feb 2020 --> May 2021 Recruiting --> Enrolling by invitation
- | GZ402668 / Sanofi
Trial completion: A First-in-human, Single Ascending Dose Study of GZ402668 in Patients With Progressive Multiple Sclerosis (clinicaltrials.gov) - Apr 13, 2016
P1, N=48, Completed, Sponsor: Genzyme, a Sanofi Company
Recruiting --> Enrolling by invitation Active, not recruiting --> Completed
- GZ402668 / Sanofi
Enrollment closed: A First-in-human, Single Ascending Dose Study of GZ402668 in Patients With Progressive Multiple Sclerosis (clinicaltrials.gov) - Mar 4, 2016
P1, N=44, Active, not recruiting, Sponsor: Genzyme, a Sanofi Company
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- GZ402668 / Sanofi
Enrollment open, Phase classification: A Long-term Follow-up Study Of Multiple Sclerosis Patients Who Participated In Genzyme-sponsored Studies of GZ402668 (clinicaltrials.gov) - Jan 28, 2015
P=N/A, N=48, Recruiting, Sponsor: Genzyme, a Sanofi Company
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting | Phase classification: P1 --> PN/A
- | GZ402668 / Sanofi
New P1 trial: A Long-term Follow-up Study Of Multiple Sclerosis Patients Who Participated In Genzyme-sponsored Studies of GZ402668 (clinicaltrials.gov) - Dec 10, 2014
P1, N=48, Not yet recruiting, Sponsor: Genzyme, a Sanofi Company
- GZ402668 / Sanofi
Enrollment open: A First-in-human, Single Ascending Dose Study of GZ402668 in Patients With Progressive Multiple Sclerosis (clinicaltrials.gov) - Dec 4, 2014
P1, N=48, Recruiting, Sponsor: Genzyme, a Sanofi Company
Not yet recruiting --> Recruiting | Phase classification: P1 --> PN/A Not yet recruiting --> Recruiting
- | GZ402668 / Sanofi
New P1 trial: A First-in-human, Single Ascending Dose Study of GZ402668 in Patients With Progressive Multiple Sclerosis (clinicaltrials.gov) - Nov 4, 2014
P1, N=48, Not yet recruiting, Sponsor: Genzyme, a Sanofi Company